Clinical trials: Acute Non-Lymphocytic Leukemia
B-cell Acute Lymphoblastic Leukemia
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride
- Trial name
- NCT00289562
- Testing
- forodesine hydrochloride (BCX-1777)
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- BioCryst Pharmaceuticals
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia
CD19-Specific T Cells Post AlloSCT
This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small…
- Conditions
- B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03579888
- Testing
- Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Relapsed AML, Refractory AML
CART123 + Ruxolitinib in Relapsed/Refractory AML
Phase I, open-label study to assess the safety, feasibility, pharmacokinetics, and preliminary efficacy of CART123 cells given in combination with ruxolitinib in patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- AML (NCT06768476)
- Testing
- CART123 Cells, Ruxolitinib 10 MG, Ruxolitinib 5 MG
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Acute Myeloid Leukaemia
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.
- Trial name
- NCT07036250
- Testing
- U32 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
This study is a Phase III, randomized, open-label, multi-center, prospective study of single umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric patients with hematologic malignancies.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00412360
- Testing
- Single Umbilical Cord Blood Unit Transplant, Double Umbilical Cord Blood Unit Transplant, Total Body Irradiation
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 224 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML.
- Trial name
- NCT00703820
- Testing
- Cytarabine, Daunorubicin, Etoposide
- Where
- 8 sites in United States, Singapore
- Volunteers
- 324 people
- Sponsor
- St. Jude Children's Research Hospital
B Cell Lymphoma, Chronic Lymphocytic Leukemia
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Patients on this study have a type of lymph gland cancer called non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "Lymphoma" or "Leukemia").
- Conditions
- B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- CRETI-NH (NCT00586391)
- Testing
- CD19CAR-28-zeta T cells, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Baylor College of Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndrome
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
This is a phase II multi-institutional therapeutic study of NK-cell based nonmyeloablative haploidentical transplantation for the treatment of high-risk acute myeloid diseases. Enrollment will use a two-stage design.
- Trial name
- NCT01370213
- Testing
- Preparative Regimen, NK Cells, Interleukin-2
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Diseases, Acute Myeloid Leukemia
Muscle Dysfunction in Patients With Haematological Diseases
PURPOSE: To evaluate the prevalence and prognostic value of sarcopenia in patients diagnosed with hematological cancer diseases.
- Conditions
- Hematologic Diseases, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT05150561
- Where
- Denmark
- Volunteers
- 216 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
This is an open label, prospective, single institution dose-escalation study. The patient population includes non-induction candidate elderly patients with AML or MDS and/or patients with high-risk or relapsed/refractory AML or…
- Trial name
- NCT00892190
- Testing
- dasatinib (SPRYCEL), all trans retinoic acid (VESANOID)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pittsburgh
Myeloid Leukemia, Acute
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their…
- Trial name
- CLEV-LAM-2022 (NCT06764459)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Leukemia
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML).
- Trial name
- NCT00008697
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05309213
- Testing
- IM19 CAR-T cells
- Volunteers
- 58 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Myelogenous Leukemia, Acute
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
This multi-center, open-label, Phase 1b study will evaluate the safety, pharmacokinetics and efficacy of RO5045337 in combination with cytarabine in patients with acute myelogenous leukemia.
- Trial name
- NCT01635296
- Testing
- RO5045377, cytarabine
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
AML (Acute Myeloid Leukemia)
FLT3-ITD Targeted Therapy in Fit AML Patients
This international, multicenter, randomized (1:1), open-label phase II/III trial will evaluate the efficacy and safety of gilteritinib combined with azacitidine and venetoclax (experimental arm) versus standard "7+3" induction…
- Trial name
- FIT-AML (NCT07425808)
- Testing
- Gilteritinib, Venetoclax, Azacitidine (AZA)
- Volunteers
- 230 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, First Line Therapy
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid…
- Trial name
- NCT06928376
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7"
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese PLA General Hospital
Acute Myeloblastic Leukemia
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
Prospective, multicenter, uncontrolled cohort study to analyze the efficacy of a risk adapted treatment strategy, including gemtuzumab ozogamicin (GO) during consolidation, for patients with acute myeloid leukemia (AML).
- Trial name
- NCT01041040
- Testing
- gemtuzumab
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- PETHEMA Foundation
B-Cell Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia
Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
This is an open-label, multi-cohort, investigator-initiated clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GI001 in adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma…
- Trial name
- GI001-01 (NCT07862010)
- Testing
- GI001
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hematology department of the 920th hospital
Relapsed/Refractory Acute Myeloid Leukemia
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
- Trial name
- NCT02665143
- Testing
- Nintedanib and AML induction
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Yale University
ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
Umbilical cord blood (UCB) is rich in haematopoietic stem progenitor cells and immune cells, and is used for transplantation for a variety of haematological disorders with the advantages of low mating requirements and fewer…
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia, MDS (Myelodysplastic Syndrome)
- Trial name
- NCT07297576
- Testing
- Sulforaphane
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.